The Critical Edge Podcast

RRT/HD Timing and AKIs

Listen Later

This podcast examines the pathophysiology, diagnosis, and clinical management of acute kidney injury (AKI) within intensive care settings. It highlights that while standardized staging systems like KDIGO help categorize the severity of renal decline, clinical decisions must still account for the underlying causes, such as ischemia or toxic exposure. The authors emphasize that preventative strategies, specifically maintaining stable blood pressure and avoiding nephrotoxic drugs, remain the most effective treatments. When the condition worsens, renal replacement therapy (RRT) becomes necessary, though the text notes that the timing of its initiation is a complex, patient-specific choice. Various dialysis modalities, including intermittent and continuous techniques, are compared based on their impact on solute clearance and hemodynamic stability. Ultimately, the source underscores that multidisciplinary care and long-term follow-up are vital for improving survival and recovery rates.

 

 

The Critical Edge is for educational and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease, nor does it substitute for professional medical advice, diagnosis, or treatment from a qualified healthcare provider—always seek in-person evaluation and care from your physician or trauma team for any health concerns.

 

 

RRT/HD Timing and AKIs: A Comprehensive Study Guide

This study guide provides a detailed synthesis of the clinical definition, diagnosis, management, and treatment modalities for acute kidney injury (AKI) and renal replacement therapy (RRT), specifically within the context of the surgical intensive care unit (SICU).

Overview of Acute Kidney Injury (AKI)

Acute kidney injury is defined as an acute decrease in the glomerular filtration rate (GFR). It is a highly prevalent condition in clinical settings, affecting approximately 20% of all hospitalized patients and up to 50% of patients admitted to the Intensive Care Unit (ICU).

Clinical Significance and Mortality

The impact of AKI on patient outcomes is significant, with mortality rates influenced by factors such as age, baseline renal function, malignancy, sepsis, and the degree of renal recovery. In the critically ill, approximately 90% of AKI episodes are attributed to ischemia or exposure to nephrotoxins. Mortality rates for patients requiring RRT range from 44% to 60%, and can reach up to 90% when AKI is associated with multisystem organ dysfunction.

Assessment of Renal Function

The kidneys regulate the volume and composition of internal fluids through four primary processes:

  1. Filtration: Passive movement of solute from plasma across the glomerular basement membrane.
  2. Secretion: Active passage of solute from blood plasma into the renal tubule lumen.
  3. Reabsorption: Active or passive passage of solute from the tubule lumen back into the blood.
  4. Excretion: The actual expulsion of urine from the collecting system.
    5. Measuring Glomerular Filtration Rate (GFR)

    The GFR represents the total volume filtered per minute, with a normal value being approximately 125 mL/min/1.73 m². Because GFR cannot be measured directly, clinical approximations are used:

    • Blood Urea Nitrogen (BUN): An end product of protein catabolism. While 80% to 90% is excreted by the kidneys, BUN levels can be skewed by high-protein diets, hematomas, gastrointestinal bleeding, or starvation, making it an unreliable independent marker for GFR.
    • Creatinine (Cr): A product of muscle degradation. Production is generally constant over the short term but diminishes with age as muscle mass decreases.
    • Creatinine Clearance (Ccr): Used to estimate GFR using the formula: Ccr = (Ucr × V) / Pcr, where Ucr is urine creatinine, V is urinary flow rate, and Pcr is serum creatinine. Note that Ccr can overestimate GFR by up to 20% due to tubular secretion.
      • Predictive Formulas

      Several formulas estimate GFR using epidemiologic data and serum creatinine:

      • Cockroft-Gault: A traditional estimation formula.
      • Modification of Diet in Renal Disease (MDRD): Commonly used for rapid estimation.
      • Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI): Modified formulas that provide more accuracy for patients with near-normal GFR.
        • Diagnostic and Staging Criteria

        The medical community has transitioned through several consensus definitions to standardize AKI diagnosis.

        Historical and Current Frameworks
        • RIFLE (2004): The first consensus definition, an acronym for Risk, Injury, Failure, Loss, and End-stage.
        • AKIN (2007): Revised RIFLE to account for the fact that even minor creatinine changes increase mortality risk. It also introduced a specific time limit for creatinine changes.
        • KDIGO (2012): The current global standard. KDIGO defines AKI as meeting at least one of the following after adequate fluid resuscitation:
          • Serum creatinine increase of > 0.3 mg/dL within 48 hours.
          • Serum creatinine increase of > 1.5 times baseline within the prior 7 days.
          • Urine output < 0.5 mL/kg/hr for at least 6 hours.
            • KDIGO Staging in Adults
            • Stage 1: Serum Cr increase of > 0.3 mg/dL or 1.5–1.9 times baseline; urine output < 0.5 mL/kg/hr for 6–12 hours.
            • Stage 2: Serum Cr 2.0–2.9 times baseline; urine output < 0.5 mL/kg/hr for ≥ 12 hours.
            • Stage 3: Serum Cr > 3 times baseline, or increase to > 4.0 mg/dL, or initiation of RRT; urine output < 0.3 mL/kg/hr for ≥ 24 hours or anuria for ≥ 12 hours.
              • Pathophysiologic Classification

              AKI is typically categorized into three etiologic groups based on the underlying cause:

              1. Prerenal: Caused by decreased renal perfusion. Examples include acute blood loss, dehydration, heart failure, and sepsis.
              2. Intrinsic: Caused by structural damage to the kidney. Examples include acute tubular necrosis (ATN), nephrotoxins, autoimmune diseases, and rhabdomyolysis.
              3. Postrenal: Caused by obstruction of the urinary tract. Examples include enlarged prostate, cancers, renal stones, and trauma.
                4. Sodium Handling and FENa

                The Fractional Excretion of Sodium (FENa) helps distinguish between prerenal and intrinsic causes by measuring the kidney’s ability to reabsorb sodium.

                • FENa < 1%: Suggests a "prerenal" state where the kidneys are conserving sodium in response to hypovolemia.
                • FENa > 2%: Suggests intrinsic renal dysfunction (such as ATN) where the tubules cannot reabsorb sodium.
                • Limitations: FENa interpretation is complicated by diuretics, congestive heart failure, and cirrhosis.
                  • Prevention Strategies

                  Prevention focuses on maintaining renal blood flow and minimizing exposure to harmful agents.

                  Hemodynamic Optimization

                  Maintaining a Mean Arterial Pressure (MAP) of at least 60–65 mm Hg is essential. Volume replacement increases glomerular hydrostatic pressure, which can prevent the progression to ATN. Conversely, volume-overloaded patients may require diuresis to improve cardiopulmonary status.

                  Limiting Nephrotoxins
                  • Antimicrobials: Vancomycin (oxidative stress), aminoglycosides (tubular damage), and amphotericin B (vasoconstriction) are common culprits. Aminoglycoside toxicity may be mitigated by once-daily dosing.
                  • Iodinated Contrast: Contrast-associated AKI (CA-AKI) is any AKI occurring within 48 hours of administration. Contrast-induced AKI (CI-AKI) specifically implicates the contrast media. Modern low-osmolality or iso-osmolar agents carry lower risks than older high-osmolality agents.
                  • Medications to Hold: ACE inhibitors, ARBs, and NSAIDs should be paused during renal instability.
                    • Pharmacologic Prevention

                    IV hydration (isotonic saline or balanced salt solutions) is the only recommended pharmacologic preventive. N-acetylcysteine (NAC) is no longer recommended. Loop diuretics and mannitol do not prevent ischemic ATN and should only be used for volume management.

                    Management of Complications
                    Acid-Base and Electrolytes
                    • Metabolic Acidosis: Often treated with alkali therapy (sodium bicarbonate), though its role is controversial. It may be most beneficial in patients with high AKIN scores (Stage 2 or 3).
                    • Hyperkalemia: Emergent treatment is required if serum potassium exceeds 5.5 mEq/L with symptoms (ECG changes, weakness). Treatment includes IV calcium for membrane stabilization, and shifting potassium intracellularly using insulin/dextrose or bicarbonate. Total body potassium is reduced via diuretics, binding resins, or RRT.
                      • Uremia and Volume Overload
                      • Uremia: Signs include encephalopathy, pericardial effusion, and platelet dysfunction. RRT is indicated once these symptoms appear.
                      • Volume Overload: Assessed via the "furosemide stress test" (1 mg/kg IV furosemide). If urine output is < 200 mL over 2 hours, the patient is at high risk for RRT requirement.
                        • Renal Replacement Therapy (RRT)
                        Initiation Criteria
                        • Emergent Indications: Severe acidosis, refractory hyperkalemia, dialyzable toxins, refractory volume overload with cardiopulmonary compromise, and clinical uremia.
                        • Elective Initiation: Recent trials (such as STAART-AKI) suggest that "accelerated" or early initiation of RRT in the absence of emergent indications does not improve survival and may increase adverse events.
                          • Principles of Solute and Fluid Removal
                          • Ultrafiltration (UF): Uses a pressure gradient (transmembrane pressure) to move water across a membrane.
                          • Diffusion: Movement of solutes from high to low concentration. Most efficient for small molecules like urea and creatinine (< 500 Da).
                          • Convection: "Solute drag" where water movement pulls both small and large molecules (like cytokines and vancomycin) through the membrane. This is used in hemofiltration.
                            • Modalities
                            • Intermittent RRT (IRRT): Typically 3–4 hours, 3–7 times a week. It allows rapid clearance but carries a 20%–30% risk of systemic hypotension.
                            • Continuous RRT (CRRT): Operates 24 hours a day. It is preferred for hemodynamically unstable patients or those with traumatic brain injury.
                              • SCUF: Isolated volume removal.
                              • CVVH: Solute clearance via convection.
                              • CVVHD: Solute clearance via diffusion.
                              • CVVHDF: Combines diffusion and convection.
                              • Prolonged Intermittent RRT (PIRRT): A hybrid approach using conventional machines at lower flow rates over 6–12 hours, offering a balance between stability and efficiency.
                                • Long-Term Outcomes

                                Survival for AKI patients discharged from the hospital is approximately 77% at one year. However, survivors are at high risk for recurrence, hypertension, cardiovascular disease, and progression to end-stage renal disease (ESRD). KDIGO guidelines recommend a nephrology follow-up within 90 days of discharge, which has been shown to reduce 2-year mortality by 24%.

                                --------------------------------------------------------------------------------

                                Glossary of Key Terms
                                • Acute Tubular Necrosis (ATN): A type of intrinsic AKI resulting from damage to the tubule cells, often due to ischemia or toxins.
                                • Azotemia: An elevation of blood urea nitrogen (BUN) and other nitrogenous waste products in the blood.
                                • Convection: The transport of solutes across a membrane along with the bulk flow of water (solute drag).
                                • Cystatin-C: An alternative biomarker for renal function currently under investigation to replace or supplement creatinine.
                                • Dialysate: An electrolyte solution used in RRT to create a concentration gradient for diffusion.
                                • Diffusion: The passive movement of solutes across a semipermeable membrane from an area of higher concentration to lower concentration.
                                • Fractional Excretion of Sodium (FENa): The ratio of sodium clearance to creatinine clearance, used to distinguish prerenal from intrinsic AKI.
                                • Glomerular Filtration Rate (GFR): The volume of fluid filtered from the renal glomerular capillaries into the Bowman's capsule per unit time.
                                • Hemofiltration: A process using high ultrafiltration rates to provide convective clearance of solutes.
                                • Nephrotoxin: A substance that is toxic to the kidneys.
                                • Oliguria: Low urine output, defined in KDIGO as < 0.5 mL/kg/hr.
                                • Ultrafiltration: The process of moving water across a semipermeable membrane using a pressure gradient.
                                • Uremia: A clinical syndrome associated with the accumulation of urea and other toxins in the blood, leading to organ dysfunction.
                                  • ...more
                                  View all episodesView all episodes
                                  Download on the App Store
                                  The Critical Edge PodcastBy The Critical Edge